

CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC

Form SC TO-C

May 15, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE TO/C  
(Rule 14d-100)**

**TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Cambridge Antibody Technology Group plc**

(Name of Subject Company (Issuer))

**AstraZeneca PLC**

(Names of Filing Persons (Offeror))

**Ordinary Shares**

**American Depositary Shares**

(Title of Class of Securities)

**Ordinary Shares (GB0001662252)**

**American Depositary Shares (US1321481079)**

(CUSIP Number of Class of Securities)

**Graeme Musker**

**AstraZeneca PLC**

**15 Stanhope Gate**

**London W1K 1LN**

**Tel: 011 44 20 7304 5000**

(Name, Address, and Telephone Number of Person

Authorized to Receive Notices and Communications on Behalf of Filing Persons)

**CALCULATION OF FILING FEE**

**Transaction Valuation**

**Amount of Filing Fee**

Not Applicable

Not Applicable

- Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid:

Form or Registration No.:

Filing Party:

Date Filed:

- Check the box if the filing relates solely to preliminary communications made before commencement of a tender offer.

Edgar Filing: CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC - Form SC TO-C

Check the appropriate boxes below to designate any transactions to which the statement relates:

third-party tender offer subject to Rule 14d-1.

issue tender offer subject to Rule 13e-4.

going-private transaction subject to Rule 13e-3.

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

---

<b>Exhibit</b>	<b>Description</b>
99.(a)(1)	Press announcement of the Offer, dated May 15, 2006
99.(a)(2)	Presentation to analysts by AstraZeneca PLC, dated May 15, 2006
99.(a)(3)	Script to presentation to Analysts by AstraZeneca PLC, dated May 15, 2006
99.(a)(4)	Presentation to employees of AstraZeneca PLC regarding the Offer, dated May 15, 2006
99.(a)(5)	Presentation to employees of Cambridge Antibody Technology Group plc regarding the Offer, dated May 15, 2006
99.(a)(6)	Announcement of the proposed Chief Executive Officer-designate by AstraZeneca PLC, dated May 15, 2006
99.(a)(7)	Intranet communication by AstraZeneca PLC with its employees regarding the Offer, dated May 15, 2006
99.(a)(8)	Questions and answers regarding the impact of the Offer on employees of AstraZeneca PLC, dated May 15, 2006